Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-008629
Filing Date
2025-02-03
Accepted
2025-02-03 16:15:22
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 13672
  Complete submission text file 0001104659-25-008629.txt   15579
Mailing Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Business Address 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033 908-740-4000
Merck & Co., Inc. (Filed by) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address DR NEERGAARDS VEJ 5F HOERSHOLM G7 2970
Business Address DR NEERGAARDS VEJ 5F HOERSHOLM G7 2970 004531262615
Evaxion Biotech A/S (Subject) CIK: 0001828253 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-94294 | Film No.: 25582676
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)